AbbVie Inc. (ABBV)
| Market Cap | 356.74B |
| Revenue (ttm) | 56.33B |
| Net Income (ttm) | 4.24B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.39 |
| PE Ratio | 84.55 |
| Forward PE | 16.48 |
| Dividend | $6.56 (3.25%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 5,841,667 |
| Open | 200.32 |
| Previous Close | 200.88 |
| Day's Range | 200.02 - 203.97 |
| 52-Week Range | 153.58 - 207.32 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 209.60 (+3.72%) |
| Earnings Date | Jan 31, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $209.6, which is an increase of 3.72% from the latest price.
News
How Dividend Investing Helps Parents Fund College Education Fees
More than half of parents in the United States emphasize paying for their child's college fees as a main concern. Start a UGMA custodial account early, and use the Dividend Growth Investing strategy t...
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of thi...
My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 Buys
January saw solid investment activity with $1,500 in net capital added, primarily into Business Development Companies like Owl Rock Capital, Goldman Sachs BDC, and Blackstone Secured Lending Fund. Div...
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Completion of Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials.
AbbVie Appears Ready To Move Higher
AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment char...
The Big 3: ABBV, EA, CEG
Today's Big 3 focuses on companies that couldn't be more different, but @ProsperTradingAcademy's Mike Shorr points to one thing they have in common: choppy price action. He talks about the trends he's...
AbbVie: An Undervalued Dividend Aristocrat
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets like...
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill. , Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has...
All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On
Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend...
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Allergan Medical Institute (AMI) Training Centers to offer most comprehensive, training programs accelerating providers' consultative and clinical skills Innovative curriculum will empower providers t...
Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I high...
US FDA approves AbbVie's treatment for intra-abdominal infections
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.
U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gra...
Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle® and Share Their Personal Stories. Natrelle® is the #1 Selected Breast Implant by Leading U.S. Physicians* Off...
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.
Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.
Buy, Sell, Or Hold ABBV Stock At $185?
AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, co...
2 Undervalued Dividend Stocks Ready For A Major Comeback
The economy is mixed - strong in some sectors, weak in others. I see value in cyclical stocks and healthcare, both lagging but poised for growth. One pick is a cyclical turnaround story with strong re...
AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats
AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidance ...
AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds
AbbVie Inc. reported strong Q4 2024 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care, and this offset worse-than-expected Humira erosion. 2025 guidance includes $59 billion in r...
AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript
AbbVie Inc. (NYSE:ABBV) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Rob Michael - Chief Executive Officer Je...
AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook
AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better-than-expected sales and gave strong guidance on higher demand for two of its drugs to tre...
AbbVie's newer immunology drugs are offsetting Humira's decline, sending stock up 4%
AbbVie's earnings topped estimates as it offered an upbeat view of 2025.
AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthriti...